Free tool
FAERS Monitor: Bondlido
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 215029 or its brand name (Bondlido, Lidocaine). Reports on generic versions are filed under their own applications.
Reports
49,631
Serious
36,212
73% of reports
Hospitalization
17,853
Death reported
5,053
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective3,671
- pain3,213
- fatigue3,108
- nausea3,093
- headache2,856
- off label use2,678
- dyspnoea2,217
- pneumonia2,054
- diarrhoea2,011
- sinusitis1,951
- vomiting1,886
- fall1,739
- product dose omission issue1,738
- dizziness1,733
- death1,711
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 281 |
| 2005 | 257 |
| 2006 | 318 |
| 2007 | 314 |
| 2008 | 376 |
| 2009 | 451 |
| 2010 | 531 |
| 2011 | 1,089 |
| 2012 | 1,215 |
| 2013 | 757 |
| 2014 | 1,133 |
| 2015 | 1,871 |
| 2016 | 3,208 |
| 2017 | 2,539 |
| 2018 | 3,295 |
| 2019 | 4,120 |
| 2020 | 5,396 |
| 2021 | 3,785 |
| 2022 | 3,521 |
| 2023 | 3,880 |
| 2024 | 3,956 |
| 2025 | 4,122 |
| 2026 | 3,212 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,004,528 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| sinusitisSignal | 1,951 | 8.2 | 7.9 | 12,160 |
| pneumoniaSignal | 2,054 | 2.7 | 2.6 | 2,216 |
| product dose omission issueSignal | 1,738 | 2.5 | 2.4 | 1,596 |
| painSignal | 3,213 | 2.2 | 2.1 | 2,214 |
| fallSignal | 1,739 | 2.2 | 2.1 | 1,178 |
| headache | 2,856 | 1.9 | 1.9 | 1,322 |
| vomiting | 1,886 | 1.7 | 1.6 | 557 |
| fatigue | 3,108 | 1.7 | 1.6 | 914 |
| dyspnoea | 2,217 | 1.7 | 1.6 | 598 |
| nausea | 3,093 | 1.7 | 1.6 | 837 |
| dizziness | 1,733 | 1.5 | 1.4 | 269 |
| diarrhoea | 2,011 | 1.3 | 1.3 | 161 |
| off label use | 2,678 | 1.3 | 1.3 | 189 |
| drug ineffective | 3,671 | 1.2 | 1.1 | 108 |
| death | 1,711 | 0.8 | 0.8 | 53 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.